Donald Bellgrau
Gründer bei ApopLogic Pharmaceuticals, Inc.
Profil
Donald Bellgrau is the founder of GlobeImmune, Inc. (founded in 1995) and ApopLogic Pharmaceuticals, Inc. (founded in 2006).
At ApopLogic Pharmaceuticals, Inc., he holds the title of Director & Founding Scientist.
Currently, Dr. Bellgrau is a Professor at The University of Colorado.
In the past, he worked as a Member-Scientific Staff at the Basel Institute for Immunology.
He obtained his doctorate degree from the University of Pennsylvania.
Aktive Positionen von Donald Bellgrau
| Unternehmen | Position | Beginn |
|---|---|---|
| The University of Colorado | Corporate Officer/Principal | 14.09.2009 |
ApopLogic Pharmaceuticals, Inc.
 ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | Gründer | 01.01.2006 |
Ehemalige bekannte Positionen von Donald Bellgrau
| Unternehmen | Position | Ende |
|---|---|---|
| GLOBEIMMUNE, INC. | Gründer | - |
| Basel Institute for Immunology | Corporate Officer/Principal | - |
Ausbildung von Donald Bellgrau
| University of Pennsylvania | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| GLOBEIMMUNE, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | Health Technology |
